Healthcare / Drug Manufacturers - GeneralSão Paulo
$11.40
-0.50 (-4.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $157.2M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
13.0x
↓EV/EBITDA
6.2x
↓ROE
9.7%
↑Gross Margin
32.4%
↓Debt/Equity
1.18
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.4%
FCF CAGR
+135.9%
FCF margin
5.7%
FCF / Net income
2.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.51B · net income $124.6M · FCF $313.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.51B | $5.51B | $4.94B | $4.46B | $3.99B |
| Net Income | $124.6M | $124.6M | $105.5M | $92.9M | $86.3M |
| EBITDA | $512.0M | $512.0M | $427.6M | $394.3M | $333.0M |
| EPS | 0.83 | 0.83 | 0.71 | 0.62 | 0.58 |
| Gross Margin | 32.4% | 32.4% | 31.8% | 30.9% | 31.1% |
| Operating Margin | 4.7% | 4.7% | 4.0% | 3.8% | 3.5% |
| Net Margin | 2.3% | 2.3% | 2.1% | 2.1% | 2.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.18 | 1.18 | 1.00 | 0.87 | 0.79 |
| Current Ratio | 1.81 | 1.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $313.0M | $313.0M | $66.6M | $157.2M | $23.8M |
| Returns | |||||
| ROE | 9.7% | 9.7% | 8.5% | 7.9% | 7.8% |
| Valuation | |||||
| P/E | 12.95 | 12.95 | 11.94 | 20.97 | 17.76 |
| EV/EBITDA | 6.17 | 6.17 | 5.65 | 7.43 | 7.14 |
| P/B | 1.33 | 1.33 | 1.02 | 1.65 | 1.38 |
| Growth & Yield | |||||
| Revenue Growth | 11.5% | 11.5% | 10.8% | 11.8% | — |
| EPS Growth | 17.1% | 17.1% | 14.4% | 6.9% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
6.8%
EPS terminal req.
$1.01
Spread vs growth
10.2%
5Y implied EPS CAGR
8.1%
EPS terminal req.
$1.22
Spread vs growth
9.0%
10Y implied EPS CAGR
9.0%
EPS terminal req.
$1.97
Spread vs growth
8.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+33.9%
Start / end P/E
12.3x → 13.7x
EPS bridge
0.71 → 0.83
Residual
+2.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.